{"id":23117,"date":"2025-05-13T11:53:32","date_gmt":"2025-05-13T09:53:32","guid":{"rendered":"https:\/\/elainternational.eu\/?page_id=23117"},"modified":"2025-05-14T14:47:53","modified_gmt":"2025-05-14T12:47:53","slug":"exceptional-call-for-proposals","status":"publish","type":"page","link":"https:\/\/elainternational.eu\/en\/exceptional-call-for-proposals\/","title":{"rendered":"Exceptional call for proposals"},"content":{"rendered":"\n\n
\n
\n
\n

2025 ELA clinical trial Funding Opportunity Announcement (FOA)<\/strong><\/h2>\n <\/div>\n
\n

ELA International represents national ELA associations from different countries that contribute together to the financing of research on leukodystrophies Accordingly, ELA International intends to launch a one-time funding opportunity for a program dedicated to clinical developments and clinical trials involving patients with Pelizaeus-Merzbacher disease (PMD), or preclinical studies focused on PMD.<\/p>\n <\/div>\n <\/div>\n<\/section>\n\n\n\n

\n
\n
\n

Funding Opportunity<\/strong> Purpose<\/h3>\n <\/div>\n
\n

The goal of the program is to support the clinical development of a therapy in PMD, the clinical development of products for use in PMD where no current therapy exists or where the product being developed will be superior to the existing therapy. ELA will provide a grant for a single clinical trial on safety and effectiveness that will either result in, or substantially contribute to, the validation of a therapy in PMD or market approval of these products. Applicants must include in the application an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.<\/p>\n

The purpose of this call for proposals is to encourage applications for investigator-initiated exploratory clinical trial to ELA International. The trials must address questions within the mission and research interests of ELA International and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies in PMD patients.<\/p>\n

The preclinical studies must focus on a treatment or intervention specifically targeting PMD. Projects should be at an advanced stage of development, nearing clinical application.<\/p>\n <\/div>\n <\/div>\n<\/section>\n\n\n\n

\n
\n
\n

Award<\/strong> process<\/h3>\n <\/div>\n
\n

The scientific merit of applications is determined by peer review. A Review Committee will recommend applications for funding based on the scientific merit, together with their judgment of the degree to which proposals are responsive to ELA’s mission and research priorities and have potential for high impact.<\/p>\n <\/div>\n <\/div>\n<\/section>\n\n\n\n

\n
\n
\n

How to apply<\/strong><\/h3>\n <\/div>\n
\n

Submission of a Letter of Intent (LOI) is required to apply for the 2025 ELA clinical trial FOA. To apply, simply:<\/p>\n